Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gemcitabine One Week After Laparoscopic Pancreatectomy
NCT01045941Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: All Cause Postoperative Morbidity at 1 year. Status: withdrawn.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01045941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01045941.